Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Special Series: Quality Care Symposium"'
Autor:
Robert S. Krouse, Jeff A. Sloan, Julia Mo, Joseph M. Unger, Marie Bakitas, Amy K. Darke, Dawn L. Hershman, Katherine A. Guthrie, Mark Allen O'Rourke
Publikováno v:
JCO Oncol Pract
PURPOSE: Patient-reported outcomes may be associated with cancer outcomes. We evaluated clinically significant fatigue (CSF), overall survival, adverse events (AEs), and quality of life (QOL) during cancer treatment. METHODS: We compared outcomes in
Autor:
Renato G. Martins, Cristina Merkhofer, Bernardo H. L. Goulart, Keith D. Eaton, Shasank Chennupati, Scott D. Ramsey, Qin Sun
Publikováno v:
JCO Oncol Pract
PURPOSE: The costs associated with clinical trial enrollment remain uncertain. We hypothesized that trial participation is associated with decreased total direct medical costs to health care payers in metastatic non–small-cell lung cancer. METHODS:
Autor:
Sandra A. Mitchell, David A. Chambers
Publikováno v:
Journal of Oncology Practice. 13:523-529
Publikováno v:
Journal of Oncology Practice. 12:863-866
Kevin Ashton coined the term “Internet of Things” in 2009 in the setting of supply chain management, but since that time, the Internet of Things (IoT) has had an impact on many other markets. Over the past several years, advances in computing and
Autor:
Rebecca DeBoer, Kristen Wroblewski, Olwen Hahn, Bobby Daly, Selina Chow, Gini F. Fleming, Justin Kline, Michael D. Howell, Bhakti K. Patel, Anshu Verma, Mayumi Fukui, Aditi Kumar, Hongtao Liu, Blase N. Polite, Andrew Hantel, Leah J. Witt, Jay S. Balachandran
Publikováno v:
Journal of oncology practice, vol 12, iss 10
Purpose: Terminal oncology intensive care unit (ICU) hospitalizations are associated with high costs and inferior quality of care. This study identifies and characterizes potentially avoidable terminal admissions of oncology patients to ICUs. Methods
Autor:
Kathleen M. Schmeler, Deepthi James, Linda Graviss, Thomas A. Aloia, Keith N. Myers, Shital Vachhani, K. Potts, Claire A. Marten, Charles F Levenback, Diane C. Bodurka, Larissa A. Meyer, Jolyn S. Taylor, Lynn M. Cloutier, Cheryl Hubbs, Anne K. Park, Alpa M. Nick, Tara N. Tatum, Katherine E. Cain, Shauna Fenton, Kathy M. Ware, Jennifer K. Burzawa
Publikováno v:
Journal of Oncology Practice. 12:e878-e883
Purpose: Surgical site infections (SSIs) are associated with patient morbidity and increased health care costs. Although several national organizations including the University HealthSystem Consortium (UHC), the National Surgical Quality Improvement
Autor:
Aaron Bohler, Jessica Fischer, Mary J. Mulkerin, Jason J Bergsbaken, Mary S Mably, Daniel Mulkerin
Publikováno v:
Journal of Oncology Practice. 12:e912-e923
Purpose: Use of oral chemotherapy is expanding and offers advantages while posing unique safety challenges. ASCO and the Oncology Nursing Society jointly published safety standards for administering chemotherapy that offer a framework for improving o
Autor:
Mary Beth Landrum, Aileen B. Chen, Katherine L. Kahn, Nancy L. Keating, Kenneth L. Kehl, Stacy W. Gray
Publikováno v:
Journal of Oncology Practice. 11:e267-e278
Multidisciplinary tumor board meetings are common in cancer care, but limited evidence is available about their benefits. We assessed the associations of tumor board participation and structure with care delivery and patient outcomes.As part of the C
Autor:
Julie Lawrence Kuznetsov, Suzanne Tamang, Manali I. Patel, Nigam H. Shah, Samuel G. Finlayson, Douglas W. Blayney, Yohan Vetteth
Publikováno v:
Journal of Oncology Practice. 11:e313-e319
Reduction in unplanned episodes of care, such as emergency department visits and unplanned hospitalizations, are important quality outcome measures. However, many events are only documented in free-text clinician notes and are labor intensive to dete
Autor:
Jennifer J. Griggs, Andrew J. Epstein, Craig Evan Pollack, Katrina Armstrong, Kaijun Liao, Christine M. Veenstra
Publikováno v:
Journal of Oncology Practice. 11:e304-e312
The relationship between oncologic hospital academic status and the value of care for stage II and III colon cancer is unknown.Retrospective SEER-Medicare analysis of patients age ≥ 66 years with stage II or III colon cancer and seen by medical onc